Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 19.3391
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 10309473900.0
- FreeCF/Share 1.0821
- PFCF 42.9173
- PE 64.6138
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, and Viking Therapeutics (VKTX -7.34%), which is far along in its development of an advanced GLP-1-based obesity treatment.
Read More
Herb Greenberg lays out the risks in Apple, Decker and Hims & Hers
Published: February 10, 2025 by: CNBC Television
Sentiment: Negative
Herb Greenberg, Herb Greenberg on the Street editor, joins 'Power Lunch' to discuss Apple's troubles in China, Deckers headwinds ahead and Hims and Hers core business slump.
Read More
Hims & Hers Super Bowl ad sparks controversy over weight loss drug sourcing
Published: February 10, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Brandon Gomez breaks down the controversy around the Hims & Hers Super Bowl ad.
Read More
Hims & Hers Super Bowl ad draws scrutiny from lawmakers
Published: February 10, 2025 by: Yahoo Finance
Sentiment: Neutral
Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.
Read More
Hims & Hers Health: Meme Potential Could Propel Explosive Growth
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Positive
Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Putting aside Hims meme potential, the company is still in a great position to disrupt the healthcare industry given its unique platform and business model. While Hims is building an increasingly innovative and high-quality business model, the company still faces major regulatory and competitive hurdles.
Read More
Hims & Hers stock price target according to the C&H pattern
Published: February 10, 2025 by: Invezz
Sentiment: Positive
Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has soared by almost 1,500% from its lowest level in 2023, transforming it into a leading juggernaut with a market cap of over $9.3 billion.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637